Martingale Asset Management’s Cullinan Oncology CGEM Stock Holding History

Martingale Asset Management’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13M	Buy	+61,938	New	+$920K	0.03%	512
2025 Q3	–	Sell	-20,932	Closed	-$158K	–	770
2025 Q2	$158K	Sell	20,932 -1,200	-5%	-$9.64K	﹤0.01%	766
2025 Q1	$168K	Sell	22,132 -16,413	-43%	-$157K	﹤0.01%	746
2024 Q4	$469K	Buy	38,545 +5,703	+17%	+$82K	0.01%	617
2024 Q3	$550K	Buy	32,842 +18,820	+134%	+$334K	0.01%	610
2024 Q2	$245K	Sell	14,022 -28,507	-67%	-$607K	0.01%	726
2024 Q1	$725K	Hold	42,529	–	–	0.01%	539
2023 Q4	$433K	Hold	42,529	–	–	0.01%	637
2023 Q3	$385K	Hold	42,529	–	–	0.01%	648
2023 Q2	$458K	Hold	42,529	–	–	0.01%	631
2023 Q1	$435K	Buy	42,529 +900	+2%	+$9.92K	0.01%	645
2022 Q4	$439K	Buy	41,629 +10,613	+34%	+$129K	0.01%	639
2022 Q3	$398K	Buy	+31,016	New	+$418K	0.01%	662

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Martingale Asset Management's CGEM Position: Q2 2026 in Review

Martingale Asset Management opened a new position in Cullinan Oncology (CGEM) in Q2 2026: 61,938 shares worth $1.13M. The stake represents 0.03% of the portfolio and ranks #512 among its holdings. This is a return to the name: Martingale Asset Management previously reported a position in CGEM as recently as Q2 2025.

Martingale Asset Management first reported a position in CGEM in Q3 2022 and has held it in 13 quarters since. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

Martingale Asset Management held 61,938 shares of Cullinan Oncology worth $1.13M as of Q2 2026.
Cullinan Oncology was a new Martingale Asset Management position in Q2 2026.
Cullinan Oncology made up 0.03% of Martingale Asset Management's portfolio in Q2 2026, its #512 holding.
Martingale Asset Management first reported a position in Cullinan Oncology in Q3 2022 and has held it in 13 quarters since.
183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.